Back
AbCellera Biologics Quote, Financials, Valuation and Earnings
The dark truth about AI
Click here to learn more...
Buy
60
ABCL
AbCellera Biologics
Last Price:
2.81
Seasonality Move:
-23.52%
7 Day Trial
ALL ACCESS PASS
$
7
Zero Day Options Trade LIVE Tuesday at 2 p.m. ET!
Discover The Zero Day Loophole (BEFORE Tues at 2 p.m. ET!)AbCellera Biologics Price Quote
$2.81
AbCellera Biologics Key Stats
Buy
60
AbCellera Biologics (ABCL)
is a Buy
Day range:
$2.76 - $3.05
52-week range:
$2.34 - $6.06
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
24.98
P/B ratio:
0.77%
Volume:
3.2M
Avg. volume:
2.7M
1-year change:
-44.25%
Market cap:
$830M
Revenue:
$38M
EPS:
$-0.61
How Much Does AbCellera Biologics Make?
-
How Much Are AbCellera Biologics's Sales Annually?
ABCL Revenues are $38M -
How Much Profit Does AbCellera Biologics's Make A Year?
ABCL net income is -$146.4M
Is AbCellera Biologics Growing As A Company?
-
What Is AbCellera Biologics's Growth Rate Quarterly?
Quarterly YoY revenue growth is -0.01% -
What Is AbCellera Biologics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
AbCellera Biologics Stock Price Performance
-
Did AbCellera Biologics Stock Go Up Last Month?
AbCellera Biologics share price went down by -3.77% last month -
Did ABCL's Share Price Rise Over The Last Year?
ABCL share price fell by -44.25% over the past 1 year
What Is AbCellera Biologics 52-Week High & Low?
-
What Is AbCellera Biologics’s 52-Week High Share Price?
AbCellera Biologics has traded as high as $6.06 over the past 52 weeks -
What Is AbCellera Biologics’s 52-Week Low Share Price?
AbCellera Biologics has traded as low as $2.34 over the past 52 weeks
AbCellera Biologics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy AbCellera Biologics?
-
How Much Debt Does AbCellera Biologics Have?
Total long term debt quarterly is $0 -
How Much Cash Does AbCellera Biologics Have?
Cash and short term investments quarterly total is $643.1M -
What Is AbCellera Biologics’s Book Value Per Share?
Book value per share is 3.65
Is AbCellera Biologics Cash Flow Positive?
-
What Is ABCL Cash Flow From Operations?
Cash flow from operations (TTM) is -$120.2M -
What Is AbCellera Biologics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $12.4M -
What Is AbCellera Biologics’s Cash Flow From Investing?
Cash flow from investing (TTM) is $61.4M
AbCellera Biologics Return On Invested Capital
-
Is Management Doing A Good Job?
ABCL return on invested capital is -15.55% -
What Is AbCellera Biologics Return On Assets?
ROA measures how assets are converting to revenues and is -12.09% -
What Is ABCL Return On Equity?
ROE is a measure of profitability and is -15.55%
AbCellera Biologics Earnings Date & Stock Price
-
What Is AbCellera Biologics's Stock Price Today?
A single share of ABCL can be purchased today for 2.81 -
What Is AbCellera Biologics’s Stock Symbol?
AbCellera Biologics trades on the nasdaq under the ticker symbol: ABCL -
When Is AbCellera Biologics’s Next Earnings Date?
The next quarterly earnings date for AbCellera Biologics is scheduled on February 20, 2025 -
When Is ABCL's next ex-dividend date?
AbCellera Biologics's next ex-dividend date is December 14, 2024 -
How To Buy AbCellera Biologics Stock?
You can buy AbCellera Biologics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
AbCellera Biologics Competitors
-
Who Are AbCellera Biologics's Competitors?
Below is a list of companies who compete with AbCellera Biologics or are related in some way:
AbCellera Biologics Dividend Yield
-
What Is ABCL Dividend Yield?
AbCellera Biologics’s dividend yield currently is 0% -
What Is AbCellera Biologics’s Payout Ratio?
AbCellera Biologics’s payout ratio is 0% -
When Did AbCellera Biologics Last Pay A Dividend?
The latest dividend pay date is December 14, 2024 -
What Is AbCellera Biologics’s Dividend Per Share?
AbCellera Biologics pays a dividend of $0.00 per share
AbCellera Biologics Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | -30.77% |
| Revenue: | -1.39% | -18.81% |
Analyst Recommendations
| Buy Recommendations: | 6 |
|---|---|
| Hold Recommendations: | 1 |
| Sell Recommendations: | 0 |
| Price Target: | 12.29 |
| Upside from Last Price: | 337.21% |